These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35606665)

  • 21. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Choi KS; Choi SH; Jeong B
    Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
    Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
    Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
    Sakai Y; Yang C; Kihira S; Tsankova N; Khan F; Hormigo A; Lai A; Cloughesy T; Nael K
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
    Kim D; Kim S; Kim SH; Chang JH; Yun M
    Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR Elastography Analysis of Glioma Stiffness and
    Pepin KM; McGee KP; Arani A; Lake DS; Glaser KJ; Manduca A; Parney IF; Ehman RL; Huston J
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):31-36. PubMed ID: 29074637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant IDH1 and thrombosis in gliomas.
    Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
    Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
    BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
    Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
    Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
    Kilincer A; Cebeci H; Seher N; Durmaz MS; Uysal E; Sahinoglu M; Koktekir E; Karabagli H; Karabagli P; Paksoy Y
    Turk Neurosurg; 2022; 32(5):826-833. PubMed ID: 35713257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
    Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
    Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
    Berens ME; Sood A; Barnholtz-Sloan JS; Graf JF; Cho S; Kim S; Kiefer J; Byron SA; Halperin RF; Nasser S; Adkins J; Cuyugan L; Devine K; Ostrom Q; Couce M; Wolansky L; McDonough E; Schyberg S; Dinn S; Sloan AE; Prados M; Phillips JJ; Nelson SJ; Liang WS; Al-Kofahi Y; Rusu M; Zavodszky MI; Ginty F
    PLoS One; 2019; 14(12):e0219724. PubMed ID: 31881020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.
    Goryawala M; Saraf-Lavi E; Nagornaya N; Heros D; Komotar R; Maudsley AA
    J Neuroimaging; 2020 Jan; 30(1):58-64. PubMed ID: 31868291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.